The effort, part of the agency’s ambitious Health Tech Ecosystem, aims to accelerate the industry’s progress before requirements on electronic prior authorization go into effect next year.
CMS launches initiative to speed electronic prior authorization adoption Read More »
Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening platforms.
GPCRs, radiopharma and the rise of functional peptide screening Read More »
The Labcorp agreement continues the expansion of Aura, which gives healthcare providers access to tests from companies including Quest Diagnostics.
Labcorp expands Epic pact to make full test menu available Read More »
Dolor, pesadez, hinchazón o sensación de piernas cansadas. ¿Te suena? Estos síntomas se atribuyen a menudo a trastornos venosos comunes, pero en muchos casos pueden esconder algo más complejo: el lipedema. Esta enfermedad crónica y progresiva afecta principa …
¿Problemas circulatorios en las piernas? Podrían ser síntomas de lipedema Read More »
Dr. Tomislav Mihaljevic’s appointment comes months after Oracle named another healthcare leader, former Quest Diagnostics CEO Stephen Rusckowski, to the board as the technology giant expands its reach in the sector.
Oracle adds Cleveland Clinic CEO to board of directors Read More »
Only 33% of physicians surveyed by the American Medical Association said they believed voluntary pledges made by major insurers last year to reform prior authorization would result in any meaningful difference to the industry.
Physicians skeptical of insurer pledges to reform prior authorization: survey Read More »
The Labcorp agreement continues the expansion of Aura, which gives healthcare providers access to tests from companies including Quest Diagnostics.
Labcorp expands Epic pact to make full test menu available on Aura Read More »
Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday.
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results Read More »
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data.
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
Degron adds $40M to series A, supporting immunology plans for molecular glue platform Read More »
